Rapid evaluation for heterogeneities in monoclonal antibodies by liquid chromatography/mass spectrometry with a column-switching system

Journal of Pharmaceutical and Biomedical Analysis

Volumn 67-68, Issue , 2012, Pages 1-9

  Kuribayashi, Ryosuke ^a   Hashii, Noritaka ^a   Harazono, Akira ^a   Kawasaki, Nana ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Column switching; Glycan heterogeneity; LC MS; Monoclonal antibody; Process analytical technology; Quality by design

Indexed keywords

MONOCLONAL ANTIBODY;

ACCURACY; ARTICLE; AUTOMATION; DRUG MANUFACTURE; DRUG SCREENING; LIQUID CHOMATOGRAPHY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, AFFINITY; MASS SPECTROMETRY;

EID: 84862126576     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.04.005     Document Type: Article

References (31)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
2. Brekke O.H., Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2003, 2:52-62.
3. Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 2006, 24:1241-1252.
4. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., Corvaia N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008, 9:482-501.
5. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., Yokoi H., Nakamura K., Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin. Cancer Res. 2004, 10:6248-6255.
6. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
7. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20:471-478.
8. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 2010, 30(Suppl. 1):S9-S14.
9. Galili U. The alpha-Gal epitope (Galalpha1-3Galbeta1-4GlcNAc-R) in xenotransplantation. Biochimie 2001, 83:557-563.
10. Miwa Y., Kobayashi T., Nagasaka T., Liu D., Yu M., Yokoyama I., Suzuki A., Nakao A. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation?. Xenotransplantation 2004, 11:247-253.
11. Lim A., Reed-Bogan A., Harmon B.J. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. Anal. Biochem. 2008, 375:163-172.
12. Kunkel J.P., Jan D.C., Butler M., Jamieson J.C. Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors. Biotechnol. Prog. 2000, 16:462-470.
13. Damen C.W., Chen W., Chakraborty A.B., van Oosterhout M., Mazzeo J.R., Gebler J.C., Schellens J.H., Rosing H., Beijnen J.H. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J. Am. Soc. Mass Spectrom. 2009, 20:2021-2033.
14. Wan H.Z., Kaneshiro S., Frenz J., Cacia J. Rapid method for monitoring galactosylation levels during recombinant antibody production by electrospray mass spectrometry with selective-ion monitoring. J. Chromatogr. A 2001, 913:437-446.
15. Issaq H.J., Chan K.C., Janini G.M., Conrads T.P., Veenstra T.D. Multidimensional separation of peptides for effective proteomic analysis. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2005, 817:35-47.
16. Liu A., Tweed J., Wujcik C.E. Investigation of an on-line two-dimensional chromatographic approach for peptide analysis in plasma by LC-MS-MS. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:1873-1881.
17. Heinig K., Wirz T., Gajate-Perez A. Sensitive determination of a drug candidate in dried blood spots using a TLC-MS interface integrated into a column-switching LC-MS/MS system. Bioanalysis 2010, 2:1873-1882.
18. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
19. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., Tsumoto K., Kumagai I., Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 2004, 336:1239-1249.
20. Sinha S., Pipes G., Topp E.M., Bondarenko P.V., Treuheit M.J., Gadgil H.S. Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs. J. Am. Soc. Mass Spectrom. 2008, 19:1643-1654.
21. Wagner-Rousset E., Bednarczyk A., Bussat M.C., Colas O., Corvaia N., Schaeffer C., Van Dorsselaer A., Beck A. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 872:23-37.
22. Kaschak T., Boyd D., Yan B. Characterization of glycation in an IgG1 by capillary electrophoresis sodium dodecyl sulfate and mass spectrometry. Anal. Biochem. 2011, 417:256-263.
23. Xie H., Chakraborty A., Ahn J., Yu Y.Q., Dakshinamoorthy D.P., Gilar M., Chen W., Skilton S.J., Mazzeo J.R. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010, 2.
24. Pharmaceutical Development Q8(R2): International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2009.
25. Rathore A.S., Winkle H. Quality by design for biopharmaceuticals. Nat. Biotechnol. 2009, 27:26-34.
26. Guidance for Industry, PAT - A Framework For Innovative Pharmaceutical, Development, Manufacturing and Quality Assurance 2004.
27. Paris I., Janoly-Dumenil A., Paci A., Mercier L., Bourget P., Brion F., Chaminade P., Rieutord A. Near infrared spectroscopy and process analytical technology to master the process of busulfan paediatric capsules in a university hospital. J. Pharm. Biomed. Anal. 2006, 41:1171-1178.
28. Ghorab M.K., Chatlapalli R., Hasan S., Nagi A. Application of thermal effusivity as a process analytical technology tool for monitoring and control of the roller compaction process. AAPS PharmSciTech 2007, 8:23.
29. Benedetti C., Abatzoglou N., Simard J.S., McDermott L., Leonard G., Cartilier L. Cohesive, multicomponent, dense powder flow characterization by NIR. Int. J. Pharm. 2007, 336:292-301.
30. Tabasi S.H., Moolchandani V., Fahmy R., Hoag S.W. Sustained release dosage forms dissolution behavior prediction: a study of matrix tablets using NIR spectroscopy. Int. J. Pharm. 2009, 382:1-6.
31. Rathore A.S., Bhambure R., Ghare V. Process analytical technology (PAT) for biopharmaceutical products. Anal. Bioanal. Chem. 2010, 398:137-154.